首页|皮肌炎自身抗体在间质性肺病中的研究进展

皮肌炎自身抗体在间质性肺病中的研究进展

扫码查看
肌炎抗体分为肌炎特异性自身抗体(MSA)和肌炎相关性自身抗体(MAA).不同肌炎抗体在间质性肺病(ILD)中的作用机制、临床特点及预后等方面存在异质性.在MSA中,抗黑色素瘤分化相关基因5(MDA5)抗体和抗氨酰tRNA合成酶(ARS)抗体与ILD的发生高度相关.抗MDA5抗体阳性皮肌炎(DM)患者ILD的发生率高,进展迅速,预后较差.抗ARS抗体阳性DM患者ILD的病程缓慢,对治疗反应较好,但易复发.在MAA中,抗Ro52抗体通常与MSA抗体共存,临床表现与共存抗体关系密切.就肌炎自身抗体在ILD中的研究进展进行综述.
Research progress of dermatomyositis-related autoantibodies in interstitial lung disease
Myositis antibodies are divided into myositis-specific autoantibodies(MSA)and myositis-associated autoantibodies(MAA).There are heterogeneity in the mechanism,clinical features and prognosis of interstitial lung disease(ILD)in the different myositis antibodies.In MSA,anti-melanoma differentiation-related gene 5(MDA5)antibody and anti-aminoacyl synthetase(ARS)antibody are highly correlated with the occurrence of ILD.Patients with MDA5+DM-ILD usually have a rapidly progressive and poor prognosis.The progress of ILD in ARS+DM patients was slow,and the response to treatment is good,but it is easy to relapse.In MAA,anti-Ro52 antibodies often coexist with MSA antibodies,and clinical manifestation is closely related to coexisting antibodies.This review has summarized roles of myositis antibodies in ILD.

dermatomyositisinterstitial lung diseaseantoantibodyclinical featuresprognosis

罗宴冉、史晓飞、韩磊、张贝、文路遥

展开 >

河南科技大学临床医学院(邮编 471003)

河南科技大学第一附属医院风湿免疫科

皮肌炎 间质性肺病 自身抗体 临床特点 预后

河南省医学科技攻关计划省部共建重点项目

SBGJ202002098

2024

天津医药
天津市医学科学技术信息研究所

天津医药

CSTPCD
影响因子:1.107
ISSN:0253-9896
年,卷(期):2024.52(7)
  • 1